EUVIMEDEUVIMED entdecken
Open Access

Years of life lost due to central nervous system tumor subtypes in the United States

Jakob V E Gerstl iD, Mackenzie Price, Joshua D Bernstock iD, Carol Kruchko, Lennard Spanehl, Paramesh V Karandikar, Jill S Barnholtz-Sloan, Timothy R Smith, Elizabeth B Claus, Quinn T Ostrom iD

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Jakob V E Gerstl und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Brigham and Women's Hospital, Mass General Brigham, Harvard Medical School, Boston, Massachussetts, USA. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Life Expectancy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CDC HHS, American Brain Tumor Association, Novocure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Years of life lost (YLL) is a disease burden measure quantifying the number of years lost due to premature mortality for a given disease. The present study sought to assess YLL for primary brain and other central nervous system (CNS) tumor histopathologies in the United States.

Methods

Mortality, incidence, and life expectancy data for mortalities occurring in 2018 were obtained from the National Vital Statistics System and the National Program of Cancer Registries. Tumor-specific YLL were estimated by subtracting age of death from projected life expectancy; mean YLL (mYLL) was determined to assess the impact of CNS tumor diagnosis on the individual patient level.

Results

For mortalities occurring in 2018, the total YLL due to malignant CNS tumors was 364 223 years (mYLL = 21.2 years), compared to 15 472 years (mYLL = 14.2 years) for nonmalignant tumors. Glioblastoma had the highest total YLL among malignant CNS tumors (58.8% of all primary CNS tumor YLL; mYLL = 19.8 years), and nonmalignant meningioma among nonmalignant CNS tumors (2.9% of all primary CNS tumor YLL; mYLL = 14.4 years). Malignant pediatric tumors had the greatest mYLL, with medulloblastoma having a mYLL of 61.2 years and other embryonal tumors having an mYLL of 50.7.

Conclusions

Malignant CNS tumors, glioblastoma in particular, contributed the most to total YLL, whereas pediatric CNS malignancies had the greatest mYLL. Used with other epidemiological data, the authors contend that this quantification may help rationalize the allocation of clinical and research resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsLife ExpectancyHumansUnited StatesFemaleMaleAdultMiddle AgedYoung AdultChildAdolescentAgedChild, PreschoolRegistriesSurvival RateInfantIncidencePrognosisInfant, NewbornAged, 80 and over

Stichwörter der Autor:innen

CBTRUScentral nervous system tumor(s)disability-adjusted life yeardisease burdenyears of life lost

Autor:innen und Institutionen

  • Department of Neurosurgery, Brigham and Women's Hospital, Mass General Brigham, Harvard Medical School, Boston, Massachussetts, USA.
  • Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.
  • Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
  • Chan School of Medicine, University of Massachusetts, Worcester, Massachussetts, USA.
  • Trans Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
  • School of Public Health, Yale University, New Haven, Connecticut, USA.

ORCID-Profile: Jakob V E Gerstl, Joshua D Bernstock, Quinn T Ostrom

Förderung

  • CDC HHS
  • American Brain Tumor Association
  • Novocure
  • Musella Foundation for Brain Tumor Research & Information, Inc., National Brain Tumor Society
  • Pediatric Brain Tumor Foundation
  • The Sontag Foundation
  • Uncle Kory Foundation
  • Zelda Dorin Tetenbaum Memorial Fund

Zitieren

APA

Gerstl, J. V. E., Price, M., Bernstock, J. D., Kruchko, C., Spanehl, L., Karandikar, P. V., Barnholtz-Sloan, J. S., Smith, T. R., Claus, E. B., & Ostrom, Q. T. (2025). Years of life lost due to central nervous system tumor subtypes in the United States. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf142

Vancouver

Gerstl JVE, Price M, Bernstock JD, Kruchko C, Spanehl L, Karandikar PV, et al. Years of life lost due to central nervous system tumor subtypes in the United States. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf142

BibTeX
@article{Gerstl2025,
  author = {Gerstl, Jakob V E and Price, Mackenzie and Bernstock, Joshua D and Kruchko, Carol and Spanehl, Lennard and Karandikar, Paramesh V and Barnholtz-Sloan, Jill S and Smith, Timothy R and Claus, Elizabeth B and Ostrom, Quinn T},
  title = {Years of life lost due to central nervous system tumor subtypes in the United States},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf142}
}
Kostenlos starten →